胃食道逆流症市場の2030年までの予測：製品別、薬剤タイプ別、診断別、投与経路別、流通チャネル別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の胃食道逆流症市場は2023年に53億7,000万米ドルを占め、2030年には69億3,000万米ドルに達すると予測され、予測期間中のCAGRは3.7%です。

胸焼けは、胃食道逆流症（GERD）と呼ばれる疾患によって引き起こされる灼熱感です。さらに、逆流とは、食道の下部に灼熱感をもたらす後方への移動のことで、胃の塩酸を含む内容物が再び上方へ移動する際に起こるものです。

2022年5月に国立生物工学情報センター（NCBI）が更新した論文によると、タバコ喫煙は逆流性食道炎または酸逆流の病因と考えられており、50歳以上の酸逆流の主要な危険因子と考えられています。

医薬品開発への新たなアプローチ

製薬業界はGERDの研究開発に力を注いでおり、その結果、安全で効果的な治療薬の開発が進んでいます。さらに、新しい製剤の開発だけでなく、ライフスタイルや遺伝的要因に基づいて特定の患者向けに治療法をカスタマイズする個別化医療戦略もイノベーションのひとつです。バレット食道、食道がん、呼吸器障害などのGERD関連合併症に対処することで、これらの技術革新は治療と予防により包括的なアプローチを提供します。

薬の使い過ぎと副作用

プロトンポンプ阻害薬（PPI）は、GERDの治療に使われる薬の一種であるが、副作用の危険性があるため、長期間使用すべきではないです。PPIは有用であるが、腎機能、骨の健康、栄養素の吸収不良などの問題があります。さらに、患者や医療専門家にとって、これらの副作用を管理し、短期的な症状緩和と長期的な健康のバランスをとることは困難です。

診断機器技術

GERDを早期かつ正確に診断するための重要な機会は、高解像度食道内圧測定、外来pHモニタリング、共焦点レーザー内視鏡検査などの高度な内視鏡検査法などの診断機器の継続的な改良によってもたらされます。これらの機器により、食道損傷の程度を評価し、Barrett食道などの合併症を発見し、選択された患者に最善の治療法を選択することが容易になっています。さらに、より早く正確な診断を受けることにより、症状の緩和と長期的な問題予防を目的とした、より効果的で個別化された治療を受けることができます。

薬物療法に対する耐性と抵抗性

特にプロトンポンプ阻害薬（PPI）は、患者によっては薬剤耐性や耐性を獲得する可能性があるため、長期間使用すべきではありません。これらの薬剤は時間とともに効果を失い、より高用量の投与や他の薬剤が必要になる可能性があります。さらに、症状を管理するために、より強い薬やより多くの治療を求める患者は、処方された薬に耐性を持つようになる可能性があり、治療方針の決定がより困難になり、医療費が増大する可能性があります。

COVID-19の影響：

胃食道逆流症（GERD）と世界のヘルスケア市場は、いずれもCOVID-19の大流行によって大きな影響を受けています。パンデミックが最初に引き起こしたのは、ヘルスケアサービスや、胃食道逆流症治療薬や医療機器の製造・流通を含むサプライチェーンへの混乱であったが、患者の行動やヘルスケア提供にも大きな変化がもたらされました。さらに、ロックダウンやその他の社会的距離を置く措置により、GERD患者に対する遠隔医療や遠隔モニタリングの利用が急増し、ウイルスに感染するリスクを下げながら治療を続けることが可能になっています。

予測期間中、カプセル・セグメントが最大となる見込み

胃食道逆流症では、カプセル剤が最大の市場シェアを占めると予測されます。カプセルは、その適応性、製造の簡便さ、患者に優しい特質から、広く使用されています。カプセルは、液体、半固体、固体の物質のような様々な医薬製剤を送達する実用的かつ効率的な手段を提供します。カプセルは正確な服用と飲み込みやすさを提供するため、あらゆる年齢の患者に好まれ、処方薬と市販薬の両方で人気のある選択肢となっています。さらにカプセルは、特殊医薬品、ビタミン剤、ハーブサプリメント、抗生物質の製剤化など、幅広い治療用途に使用できます。

予測期間中、ホームケア分野が最も高いCAGRが見込まれる

予測期間中、CAGRが最も高いのは在宅介護分野です。在宅介護サービスのニーズは、高齢化、快適な環境での個別ケアの要望、遠隔医療や医療技術の発展など、さまざまな要因の結果、大幅に増加しています。さらに、在宅介護サービスは、医療的・非医療的支援を幅広くカバーするため、自宅にいながら継続的なケア、モニタリング、リハビリテーションを必要とする患者にとって魅力的です。患者のニーズに応じて、理学療法、投薬管理、看護ケア、さらには複雑な医療処置までが含まれます。

最大のシェアを占める地域：

北米地域が最大の市場シェアを占めると予測されます。この地域は、強力な医薬品・医療機器産業、大規模なヘルスケア・インフラ、高額な医療支出など、多くの理由でよく知られています。特に医薬品開発と技術革新の面で、米国の医薬品産業は充実しています。北米の優位性のもう一つの要因は、国際的に認知された研究センターやヘルスケア施設が豊富にあることです。さらに、北米のヘルスケア市場は現在も変化を続けており、価値観に基づくケア、革新的な治療法、医療技術にますます重点が置かれています。

CAGRが最も高い地域：

市場のCAGRが最も高いのはアジア太平洋地域です。人口の急増、都市化の進展、ヘルスケアに対する意識の高まり、中国やインドなどの著しい経済発展など、数多くの要因がこの力強い成長の要因となっています。これらの国々では、医薬品、医療技術、ヘルスケア・インフラへの大規模な投資が行われています。さらに、アジア太平洋地域は臨床試験や研究の中心地として知られるようになり、世界中から医薬品・医療機器メーカーが集まってきています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の胃食道逆流症市場：製品別

• 錠剤
• カプセル
• サスペンション
• ソリューション
• その他の製品

第6章 世界の胃食道逆流症市場：薬剤タイプ別

• 制酸薬
• プロトンポンプ阻害剤
• H2受容体ブロッカー
• プロキネティックエージェント
• ドーパミン受容体拮抗薬
• エンドシンチ
• ストレッタ
• エソフィクス
• 経口的切開なし
• 噴門形成術
• 他の種類の薬剤

第7章 世界の胃食道逆流症市場：診断別

• 上部内視鏡検査
• 外来酸（pH）プローブ検査
• 食道内圧測定
• その他の診断

第8章 世界の胃食道逆流症市場：投与経路別

• 経口
• 静脈

第9章 世界の胃食道逆流症市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 世界の胃食道逆流症市場：エンドユーザー別

• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー

第11章 世界の胃食道逆流症市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第12章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第13章 企業プロファイル

• Medtronic Plc
• Takeda Pharmaceutical Company Limited.
• Johnson & Johnson Services Inc.
• GlaxoSmithKline PLC
• Olympus Corporation
• TWi Pharmaceuticals, Inc.
• Ironwood Pharmaceuticals, Inc.
• SRS Life Sciences
• Reckitt Benckiser Group PLC
• Zydus Group
• AstraZeneca PLC
• Camber Pharmaceuticals, Inc.
• Pfizer Inc.
• Teva Pharmaceuticals Industries Limited.
• Aurobindo Pharma
• Sebela Pharmaceuticals
• Phathom Pharmaceuticals, Inc.
• SFJ Pharmaceuticals

List of Tables

• Table 1 Global Gastroesophageal Reflux Disease Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Gastroesophageal Reflux Disease Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Gastroesophageal Reflux Disease Market Outlook, By Tablet (2021-2030) ($MN)
• Table 4 Global Gastroesophageal Reflux Disease Market Outlook, By Capsule (2021-2030) ($MN)
• Table 5 Global Gastroesophageal Reflux Disease Market Outlook, By Suspension (2021-2030) ($MN)
• Table 6 Global Gastroesophageal Reflux Disease Market Outlook, By Solution (2021-2030) ($MN)
• Table 7 Global Gastroesophageal Reflux Disease Market Outlook, By Other Products (2021-2030) ($MN)
• Table 8 Global Gastroesophageal Reflux Disease Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 9 Global Gastroesophageal Reflux Disease Market Outlook, By Antacids (2021-2030) ($MN)
• Table 10 Global Gastroesophageal Reflux Disease Market Outlook, By Proton Pump Inhibitors (2021-2030) ($MN)
• Table 11 Global Gastroesophageal Reflux Disease Market Outlook, By H2 Receptor Blocker (2021-2030) ($MN)
• Table 12 Global Gastroesophageal Reflux Disease Market Outlook, By Pro Kinetic Agents (2021-2030) ($MN)
• Table 13 Global Gastroesophageal Reflux Disease Market Outlook, By Dopamine Receptor Antagonist (2021-2030) ($MN)
• Table 14 Global Gastroesophageal Reflux Disease Market Outlook, By EndoCinch (2021-2030) ($MN)
• Table 15 Global Gastroesophageal Reflux Disease Market Outlook, By Stretta (2021-2030) ($MN)
• Table 16 Global Gastroesophageal Reflux Disease Market Outlook, By EsophyX (2021-2030) ($MN)
• Table 17 Global Gastroesophageal Reflux Disease Market Outlook, By Transoral Incisionless (2021-2030) ($MN)
• Table 18 Global Gastroesophageal Reflux Disease Market Outlook, By Fundoplication (2021-2030) ($MN)
• Table 19 Global Gastroesophageal Reflux Disease Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 20 Global Gastroesophageal Reflux Disease Market Outlook, By Diagnosis (2021-2030) ($MN)
• Table 21 Global Gastroesophageal Reflux Disease Market Outlook, By Upper Endoscopy (2021-2030) ($MN)
• Table 22 Global Gastroesophageal Reflux Disease Market Outlook, By Ambulatory Acid (pH) Probe Test (2021-2030) ($MN)
• Table 23 Global Gastroesophageal Reflux Disease Market Outlook, By Esophageal Manometry (2021-2030) ($MN)
• Table 24 Global Gastroesophageal Reflux Disease Market Outlook, By Other Diagnosis (2021-2030) ($MN)
• Table 25 Global Gastroesophageal Reflux Disease Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 26 Global Gastroesophageal Reflux Disease Market Outlook, By Oral (2021-2030) ($MN)
• Table 27 Global Gastroesophageal Reflux Disease Market Outlook, By Parental (2021-2030) ($MN)
• Table 28 Global Gastroesophageal Reflux Disease Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 29 Global Gastroesophageal Reflux Disease Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 30 Global Gastroesophageal Reflux Disease Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 31 Global Gastroesophageal Reflux Disease Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 32 Global Gastroesophageal Reflux Disease Market Outlook, By End User (2021-2030) ($MN)
• Table 33 Global Gastroesophageal Reflux Disease Market Outlook, By Hospital (2021-2030) ($MN)
• Table 34 Global Gastroesophageal Reflux Disease Market Outlook, By Homecare (2021-2030) ($MN)
• Table 35 Global Gastroesophageal Reflux Disease Market Outlook, By Specialty Clinics (2021-2030) ($MN)
• Table 36 Global Gastroesophageal Reflux Disease Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Gastroesophageal Reflux Disease Market is accounted for $5.37 billion in 2023 and is expected to reach $6.93 billion by 2030 growing at a CAGR of 3.7% during the forecast period. Heartburn is a burning sensation that is brought on by a condition called gastroesophageal reflux disease (GERD). Moreover, reflux, a backward movement that produces a burning sensation in the lower part of the esophagus, is what happens when the stomach's hydrochloric acid-containing contents travel upward again.

According to an article updated by the National Center for Biotechnology Information (NCBI) in May 2022, tobacco smoking is considered an etiological factor of reflux esophagitis or acid reflux and it is considered a major risk factor for acid reflux over the age of 50.

Market Dynamics:

Driver:

New approaches to drug development

The pharmaceutical industry's dedication to GERD research and development has resulted in the development of increasingly safe and effective drugs for the condition's management. Additionally, innovations include not only the creation of new drug formulations but also personalized medicine strategies that customize treatments for specific patients based on lifestyle and genetic factors. By addressing GERD-related complications like Barrett's esophagus, esophageal cancer, and respiratory disorders, these innovations offer a more all-encompassing approach to treatment and prevention.

Restraint:

Overuse and adverse reactions to medication

Proton pump inhibitors (PPIs), one type of medication used to treat GERD should not be used for an extended period of time due to the risk of side effects. PPIs are useful, but they raise questions about kidney function, bone health, and nutrient malabsorption. Furthermore, it can be difficult for patients and healthcare professionals to manage these side effects and strike a balance between short-term symptom relief and long-term health.

Opportunity:

Technologies for diagnostic instruments

An important opportunity for the early and precise diagnosis of GERD is provided by continuous improvements in diagnostic tools, such as high-resolution esophageal manometry, ambulatory pH monitoring, and sophisticated endoscopy methods like confocal laser endomicroscopy. These instruments facilitate the evaluation of the degree of esophageal injury, the detection of complications such as Barrett's esophagus, and the choice of the best course of action for selected patients. Moreover, patients can receive more effective and individualized treatments aimed at symptom relief and long-term problem prevention with an earlier and more accurate diagnosis.

Threat:

Tolerance and resistance to medication

Proton pump inhibitors (PPIs) in particular should not be used for extended periods of time, as some patients may develop drug resistance and tolerance. It is possible that these drugs will lose their effectiveness with time and that higher doses or other medications will be necessary. Additionally, patients who seek stronger medications or more therapies to manage their symptoms may become resistant to their prescribed medications, which can make treatment decisions more difficult and raise medical expenses.

COVID-19 Impact:

Gastroesophageal reflux disease (GERD) and the global healthcare market have both been significantly impacted by the COVID-19 pandemic. Significant changes in patient behavior and healthcare delivery were also brought about by the pandemic, even though it first caused disruptions to healthcare services and supply chains, including the manufacture and distribution of GERD medications and medical devices. Furthermore, lockdowns and other social distancing measures led to a spike in the use of telemedicine and remote monitoring for GERD patients, which allowed for continued care while lowering the risk of contracting the virus.

The Capsule segment is expected to be the largest during the forecast period

It is projected that the capsule segment will command the largest market share for gastroesophageal reflux disease. Because of their adaptability, simplicity in production, and patient-friendly qualities, capsules are widely used. They offer a practical and efficient means of delivering a variety of pharmaceutical formulations, such as liquid, semi-solid, or solid substances. Patients of all ages prefer capsules because they provide accurate dosing and ease of swallowing, making them a popular choice for both prescription and over-the-counter medications. Furthermore, capsules can be used for a wide range of therapeutic applications, including the formulation of specialty drugs, vitamins, herbal supplements, and antibiotics.

The Homecare segment is expected to have the highest CAGR during the forecast period

Over the course of the projection period, the homecare segment has shown the highest CAGR. The need for homecare services has increased significantly as a result of a number of factors, such as the aging population, the desire for individualized care in comfortable settings, and developments in telehealth and medical technology. Moreover, homecare services are appealing for patients who need ongoing care, monitoring, or rehabilitation while remaining in their own homes because they cover a wide range of medical and non-medical assistance. Depending on the patient's needs, these services can include physical therapy, medication management, nursing care, and even complex medical procedures.

Region with largest share:

The region of North America is projected to possess the largest market share. The region is well-known for a number of reasons, including a strong pharmaceutical and medical device industry, a large healthcare infrastructure, and high healthcare spending. Particularly in terms of drug development and innovation, the pharmaceutical industry in the United States is substantial. Another factor in North America's dominance is the abundance of internationally recognized research centers and healthcare facilities. Additionally, the North American healthcare market is still changing, with an increasing emphasis on value-based care, innovative therapies, and medical technology.

Region with highest CAGR:

The market's highest CAGR is being experienced by the Asia-Pacific region. Numerous factors, such as the fast-growing population, growing urbanization, increased awareness of healthcare, and significant economic development in nations like China and India, can be credited for this robust growth. These countries are seeing large investments in pharmaceuticals, medical technology, and healthcare infrastructure. Furthermore, the Asia-Pacific area is becoming known as a center for clinical trials and research, drawing pharmaceutical and medical device manufacturers from throughout the world.

Key players in the market

Some of the key players in Gastroesophageal Reflux Disease market include: Medtronic Plc, Takeda Pharmaceutical Company Limited., Johnson & Johnson Services Inc., GlaxoSmithKline PLC, Olympus Corporation, TWi Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., SRS Life Sciences, Reckitt Benckiser Group PLC, Zydus Group, AstraZeneca PLC, Camber Pharmaceuticals, Inc., Pfizer Inc., Teva Pharmaceuticals Industries Limited., Aurobindo Pharma, Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc. and SFJ Pharmaceuticals.

Key Developments:

In May 2023, Medtronic plc, a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch® device a tubeless, wearable and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology™ algorithm and next-generation continuous glucose monitor, is expected to expand the company's ability to address the needs of more individuals with diabetes, no matter where they are in their treatment journey or preference for how they want their insulin delivered.

In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

In January 2023, Takeda has signed an exclusive licence agreement with HUTCHMED (China) and its subsidiary HUTCHMED to develop and market the latter's fruquintinib. Under the deal terms, the company will have an exclusive global licence for the development and commercialisation of fruquintinib for all indications and territories outside of mainland China, Macau, and Hong Kong.

Products Covered:

• Tablet
• Capsule
• Suspension
• Solution
• Other Products

Drug Types Covered:

• Antacids
• Proton Pump Inhibitors
• H2 Receptor Blocker
• Pro Kinetic Agents
• Dopamine Receptor Antagonist
• EndoCinch
• Stretta
• EsophyX
• Transoral Incisionless
• Fundoplication
• Other Drug Types

Diagnosis Covered:

• Upper Endoscopy
• Ambulatory Acid (pH) Probe Test
• Esophageal Manometry
• Other Diagnosis

Route of Administrations Covered:

• Oral
• Parental

Distribution Channels Covered:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

End Users Covered:

• Hospital
• Homecare
• Specialty Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Gastroesophageal Reflux Disease Market, By Product

• 5.1 Introduction
• 5.2 Tablet
• 5.3 Capsule
• 5.4 Suspension
• 5.5 Solution
• 5.6 Other Products

6 Global Gastroesophageal Reflux Disease Market, By Drug Type

• 6.1 Introduction
• 6.2 Antacids
• 6.3 Proton Pump Inhibitors
• 6.4 H2 Receptor Blocker
• 6.5 Pro Kinetic Agents
• 6.6 Dopamine Receptor Antagonist
• 6.7 EndoCinch
• 6.8 Stretta
• 6.9 EsophyX
• 6.10 Transoral Incisionless
• 6.11 Fundoplication
• 6.12 Other Drug Types

7 Global Gastroesophageal Reflux Disease Market, By Diagnosis

• 7.1 Introduction
• 7.2 Upper Endoscopy
• 7.3 Ambulatory Acid (pH) Probe Test
• 7.4 Esophageal Manometry
• 7.5 Other Diagnosis

8 Global Gastroesophageal Reflux Disease Market, By Route of Administration

• 8.1 Introduction
• 8.2 Oral
• 8.3 Parental

9 Global Gastroesophageal Reflux Disease Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Hospital Pharmacy
• 9.3 Online Pharmacy
• 9.4 Retail Pharmacy

10 Global Gastroesophageal Reflux Disease Market, By End User

• 10.1 Introduction
• 10.2 Hospital
• 10.3 Homecare
• 10.4 Specialty Clinics
• 10.5 Other End Users

11 Global Gastroesophageal Reflux Disease Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Medtronic Plc
• 13.2 Takeda Pharmaceutical Company Limited.
• 13.3 Johnson & Johnson Services Inc.
• 13.4 GlaxoSmithKline PLC
• 13.5 Olympus Corporation
• 13.6 TWi Pharmaceuticals, Inc.
• 13.7 Ironwood Pharmaceuticals, Inc.
• 13.8 SRS Life Sciences
• 13.9 Reckitt Benckiser Group PLC
• 13.10 Zydus Group
• 13.11 AstraZeneca PLC
• 13.12 Camber Pharmaceuticals, Inc.
• 13.13 Pfizer Inc.
• 13.14 Teva Pharmaceuticals Industries Limited.
• 13.15 Aurobindo Pharma
• 13.16 Sebela Pharmaceuticals
• 13.17 Phathom Pharmaceuticals, Inc.
• 13.18 SFJ Pharmaceuticals